| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 4,606,289 | 5,914,980 | ||
| Prepaid expenses and other current assets | 407,543 | 163,647 | ||
| Total current assets | 5,013,832 | 6,078,627 | ||
| Intangible assets, net | 2,925 | 3,066 | ||
| Equity method investment | 643,090 | 720,010 | ||
| Total assets | 5,659,847 | 6,801,703 | ||
| Accounts payable, related party-Related Party | - | 0 | ||
| Accounts payable | 556,284 | 671,118 | ||
| Accrued expenses | 598,472 | 539,909 | ||
| Total current liabilities | 1,154,756 | 1,211,027 | ||
| Total liabilities | 1,154,756 | 1,211,027 | ||
| Common stock, 100,000,000 shares authorized with a par value of 0.001 per share, 23,836,383 and 6,474,588 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 23,836 | 21,535 | ||
| Additional paid in capital | 92,457,586 | 91,751,821 | ||
| Accumulated deficit | -87,976,331 | -86,182,680 | ||
| Total stockholders equity | 4,505,091 | 5,590,676 | ||
| Total liabilities and stockholders equity | 5,659,847 | 6,801,703 | ||
ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC. (ADIL)